Clinical Trials Browser

Phase 2 × Breast Neoplasms × Ipilimumab × Clear all

NCT03789110 2026-02-06

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

Phase 2 Active not recruiting

30 enrolled 15 charts

Breast Neoplasms

NCT03546686 2025-10-27

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT03650894 2025-03-10

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Phase 2 Active not recruiting

Breast Neoplasms

NCT03409198 2024-10-15

ICON

Phase 2 Completed

Breast Neoplasms, Neoplasms

NCT06342037 2024-09-19

TONIC-3

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03815890 2024-05-30

BELLINI

Phase 2 Recruiting

Breast Neoplasms

NCT03818685 2024-02-12

BreastImmune03

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT03342417 2021-11-09

Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients

Phase 2 Terminated

BreastGastrointestinalGynecologic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT02892734 2020-07-16

Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer

Phase 2 Terminated

3 enrolled 11 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00083278 2012-04-27

Study of MDX-010 in Stage IV Breast Cancer

Phase 2 Completed

Adenocarcinoma, Breast Neoplasms